Latest News

(UroToday.com) Renal cell carcinoma is the most common kidney cancer and constitutes approximately 3% of all malignant tumors in adults. Renal cell carcinoma is often first detected at an advanced stage, with 25% to 30% of patients with metastatic disease at diagnosis. Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting PD-L1 that was […]

(UroToday.com) At the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, during the session on sequencing therapies in advanced kidney cancer in the contemporary era, Dr. Laurence Albiges presenting on novel therapeutics on the horizon for advanced kidney cancer.

(UroToday.com) At the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, a session on sequencing therapies in advanced kidney cancer in the contemporary era included a discussion by Dr. Rana McKay presenting on practical systemic therapy considerations after frontline immunotherapy combination.

(UroToday.com)  There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition to the forefront, subsequent studies have examined combinations of immune checkpoint […]

(UroToday.com) At the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting,  during the session entitled “Breaking Barriers: Ensuring Equity in Cancer Diagnosis, Treatment, and Trial Enrollment for Patients with Kidney and Bladder Cancers,” Dr. Ravindran Kanesvaran presented on how we may optimize care, including clinical trial enrollments for older patients with kidney and bladder […]

(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition to the forefront, subsequent studies have examined combinations of immune checkpoint inhibitors […]

(UroToday.com) As part of the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, a session entitled “Breaking Barriers: Ensuring Equity in Cancer Diagnosis, Treatment, and Trial Enrollment for Patients with Kidney and Bladder Cancers”, Dr. Hoffman-Censits presented on bladder cancer in women.

(UroToday.com) At the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, during the session entitled “Breaking Barriers: Ensuring Equity in Cancer Diagnosis, Treatment, and Trial Enrollment for Patients with Kidney and Bladder Cancers,” Dr. Chana Weinstock presented the role of the FDA to create a regulatory environment to encourage diversity in the modern era of […]

(UroToday.com) The bladder cancer poster discussion session at American Society of Clinical Oncology (ASCO) 2021 featured a discussant presentation by Dr. Bishoy Faltas examining novel immunotherapy approaches across the spectrum of urothelial cancer stages.

(UroToday.com) BCG is effective in the management of high-risk non-muscle-invasive bladder cancer (NMIBC), but recurrences are frequent. Furthermore, second-line therapies for BCG-unresponsive high-risk NMIBC remain inadequate. Radical cystectomy is the standard of care for patients with BCG-unresponsive high-risk NMIBC, but many patients are unfit for surgery or elect bladder preservation. At the 2021 American Society of Clinical […]